The Y90 procedure, formally called yttrium-90 radioembolization, is a minimally invasive treatment that delivers targeted radiation directly to liver tumors through tiny radioactive beads. A doctor threads a catheter through an artery in your groin up to the blood vessels feeding the tumor, then injects millions of microscopic spheres loaded with a radioactive element called yttrium-90. These spheres lodge in the small blood vessels surrounding the tumor and emit radiation that destroys cancer cells from the inside, while largely sparing healthy liver tissue.
How Y90 Works Inside the Liver
Liver tumors get most of their blood supply from the hepatic artery, while healthy liver tissue is fed primarily by the portal vein. This quirk of anatomy is what makes Y90 effective. When radioactive microspheres are injected into the hepatic artery, they travel preferentially into the tumor’s blood supply. Studies show the spheres deposit in tumor tissue at a ratio of 3:1 to as high as 20:1 compared to surrounding normal liver, with most accumulating around the edges of tumor nodules where growth is most active.
Yttrium-90 is a pure beta radiation emitter, meaning its radiation travels only about 2.5 millimeters into tissue. That short range is the key safety feature: the spheres irradiate a tiny zone around wherever they land, delivering intense doses to the tumor while the radiation essentially can’t reach far enough to damage distant healthy tissue. Y90 has a half-life of 2.67 days, so over 95% of the radiation is deposited within two weeks of injection. Unlike chemoembolization (TACE), which relies heavily on cutting off blood supply and delivering chemotherapy drugs, Y90’s anti-tumor effect comes almost entirely from radiation, with only a minor contribution from blocking blood flow.
Who Is a Candidate
Y90 is most commonly used for hepatocellular carcinoma (HCC), the most common form of primary liver cancer. It’s incorporated into treatment guidelines from major organizations including the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO). It works particularly well for patients with advanced-stage HCC, including those whose tumors have grown into nearby blood vessels, as long as liver function is still reasonably preserved.
Beyond primary liver cancer, Y90 is also used to treat cancers that have spread to the liver from other parts of the body. Colorectal cancer liver metastases, neuroendocrine tumor metastases, and intrahepatic cholangiocarcinoma (bile duct cancer) are all recognized indications. In each of these cases, Y90 is now considered a key component of the treatment algorithm for liver tumors.
Certain conditions rule out Y90 treatment. Absolute contraindications include pregnancy, a life expectancy under three months, significant liver impairment, and widespread cancer outside the liver. Relative concerns that may disqualify some patients include poor liver function scores, tumors replacing more than 50 to 70 percent of the liver, severe kidney failure, and prior external beam radiation to the liver area.
The Mapping Procedure
Before the actual Y90 treatment, you’ll undergo a separate planning session sometimes called a mapping angiogram. During this visit, a doctor threads a catheter into the hepatic artery and injects a tracer to map your liver’s blood supply. The main purpose is to measure something called the lung shunt fraction: because some blood from the liver flows to the lungs, doctors need to confirm that the radioactive spheres won’t travel there in dangerous quantities. In most patients, the lung shunt fraction is low (typically around 5%), meaning the lung dose stays clinically negligible. This mapping session also identifies any blood vessels that might accidentally carry spheres to the stomach or intestines, which would need to be blocked before treatment.
What Happens on Treatment Day
The treatment itself follows a similar path to the mapping procedure. You’ll receive sedation, and an interventional radiologist will guide a catheter through a small puncture in your groin artery up to the blood vessels feeding your liver tumor. Once the catheter is positioned, the radioactive microspheres are slowly injected. The entire process typically takes a few hours.
Two types of microspheres are currently available: glass spheres and resin spheres. Glass spheres are smaller (20 to 30 micrometers) and carry more radioactivity per sphere, while resin spheres are slightly larger (20 to 60 micrometers) and carry less radioactivity per individual bead. The choice between them depends on your medical team’s protocol. With resin spheres, both lobes of the liver can sometimes be treated on the same day, while glass sphere treatments for both lobes are typically done in separate sessions about a month apart.
Most patients either go home the same day after a few hours of observation or stay overnight and leave the next morning.
Recovery and Side Effects
Most people return to normal activities within one week. For the first 24 hours, you should not drive, operate machinery, drink alcohol, or make important legal or financial decisions due to the effects of sedation. For the first 48 to 72 hours, avoid lifting anything heavier than about 10 pounds and skip strenuous exercise to let the catheter puncture site heal.
The most common side effect is post-embolization syndrome, a cluster of symptoms including fatigue, nausea, abdominal pain, and low-grade fever. This reaction is significantly less common and less severe with Y90 than with chemoembolization. After chemoembolization, 60 to 80 percent of patients experience these symptoms, but hospitalizations for post-embolization syndrome after Y90 are considerably rarer. When symptoms do occur, they typically appear within 24 to 72 hours, though in some cases onset can be delayed by several days.
Fatigue is the most frequently reported complaint and can linger for a few weeks in some patients. Serious complications, such as radiation damage to the stomach, intestines, or lungs, are uncommon when the pre-treatment mapping has been done properly.
Radiation Safety at Home
Because you’ll have radioactive material in your body after the procedure, you’ll need to take precautions for the first three to seven days. Your radiation safety officer will give you specific guidelines, but typical recommendations include avoiding sleeping in the same bed as your partner, limiting close contact with children and pregnant women, and not sitting next to someone on public transportation for more than two hours. These precautions are temporary. With Y90’s short half-life, the vast majority of the radiation is gone within two weeks.
How Y90 Fits Into Cancer Treatment
Y90 is rarely used as the only treatment for liver cancer. It often serves as one component of a broader strategy. For some patients with early-stage tumors, Y90 can shrink a tumor enough to make surgical removal or liver transplantation possible. For patients with more advanced disease, it can control tumor growth and extend survival, sometimes in combination with systemic therapies. In cases of liver metastases from colorectal or neuroendocrine cancers, Y90 provides a way to target liver-confined disease when chemotherapy alone isn’t controlling it.
The treatment can be repeated if needed, and because it preserves more healthy liver tissue than some alternatives, patients who respond well may remain candidates for additional therapies down the line.